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Introduction
Current prevention guidelines focus on low-density lipoprotein 
(LDL) cholesterol lowering as the primary target of therapy, primarily 
by statins.1) However, many statin-treated individuals continue to 
experience cardiovascular events.2-5) Even after low LDL cholesterol 
levels (70-100 mg/dL) are achieved, residual cardiovascular risk is 
observed in the randomized clinical trials of high dose statins.2)5) For 
further reduction of residual cardiovascular risk, physicians should 
pay attention to modifiable risk factors such as hypertriglyceridemia, 
non-high-density lipoprotein (HDL) cholesterol, apolipoprotein B, 
low HDL cholesterol, visceral fat, and insulin resistance. As one of the 
correctable residual cardiovascular risk factors, hypertriglyceridemia 
is recently reemerging as one of the reliable therapeutic targets. In 
Asians, such as Koreans, Chinese, and Japanese, the prevalence of 
hypertriglyceridemia is greater than hypercholesterolemia within the 
Korean population,6-8) Chinese National Survey,9) and Japanese men 
(http://www.mhlw.go.jp/bunya/kenkou/eiyou/h25-houkoku.html). 
In addition, a 2007 Korean National Survey also revealed 33.2% of 
the general population had hypertriglyceridemia (triglycerides≥150 
mg/dL) and 50.2% of them showed low HDL cholesterol levels 
(men<40 mg/dL, women<50 mg/dL).10) It is important to mention 
that recent genetic studies and randomized trials demonstrated 
that low HDL cholesterol might not be a cause of cardiovascular 
disease and hypertriglyceridemia and remnant cholesterol may 
be a cause.11) In this review, we reviewed updated evidence of the 
role of hypertriglyceridemia and triglyceride-rich lipoproteins 
(TRLs), remnant cholesterol as cardiovascular risk factors and the 
therapeutic target for reducing residual cardiovascular risk. 
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Recent Evidence of the Role of Hypertriglyceride-
mia and Triglyceride-Rich Lipoproteins as Cardio-
vascular Risk Factors
Experimental evidence 
TRLs are too large to enter into the arterial intima and therefore 
cannot lead to development of atherosclerosis at greatly elevated 
triglycerides (TG) concentrations (>4450 mg/dL). By contrast, at 
mild to moderately raised TG concentrations (178-890 mg/dL), TRLs 
are small enough to enter into the arterial wall and thus have the 
potential to accumulate and cause atherosclerosis.11-13)
TRLs include chylomicrons, very large density lipoprotein (VLDL) 
Fig. The production of TRLs, remnant cholesterol which induces the formation of atherosclerosis. TRLs include chylomicrons, VLDL and IDL. Their major 
protein component is apolipoprotein B. In the fasting state, only VLDL and IDL are present in plasma, whereas chylomicrons, VLDL and their remnants 
circulate under non-fasting conditions. TRLs undergoes intravascular hydrolysis by lipoprotein lipase in muscle, adipose tissue, heart and other tissues, 
where they provide free fatty acids for energy or storage. Upon lipolysis, chylomicrons and VLDL are depleted of TG and enriched in cholesterol, resulting 
in the formation of chylomicron remnants and VLDL remnants. CETP mediates major lipid transfer and exchange between HDL and TRLs. During this 
process, cholesteryl esters are transferred from HDL to TRLs and TG move from TRLs to HDL. In addition, the plasma HDL pool involves hydrolysis of TG in 
VLDL, IDL, and chylomicrons. In this process, which is catalyzed by LPL, phospholipids as well as several apolipoproteins (such as apoCI, CII, CIII) are 
transferred to HDL. Since most cells can degrade TG, and there are not any cells that can degrade cholesterol, the cholesterol content of TRLs is more likely 
to be the cause of atherosclerosis and cardiovascular disease rather than raised TG per se. Indeed, cholesterol, rather than TG accumulates in intimal foam 
cells and in atherosclerotic plaques, and remnant lipoproteins like LDL can enter the arterial intima. In contrast, chylomicrons are too large to enter. LPL 
activity at the surface of remnant particles, either at the surface of vascular endothelium or within the intima, leads to liberation of free fatty acids, 
monoacylglycerols, and other molecules, each of which could cause local injury and inflammation. Although other possible mechanisms  have been 
suggested, perhaps the simplest chain of events is that high triglyceride concentrations are a marker for raised remnants rich in cholesterol, which, upon 
entrance into the intima, leads to low-grade inflammation, foam cell formation, atherosclerotic plaques, and ultimately cardiovascular disease and 
increased mortality.11) TRLs: triglyceride rich lipoproteins, VLDL: very large density lipoprotein, IDL: intermediate density lipoprotein, TG: triglyceride, LDL: low 
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and intermediate density lipoprotein (IDL). Their major protein 
component is apolipoprotein B. In the fasting state, only VLDL and 
IDL are present in plasma, whereas chylomicrons, VLDL and their 
remnants circulate under non-fasting conditions. TRLs undergo 
intravascular hydrolysis by lipoprotein lipase in the muscle, 
adipose tissue, heart and other tissues, where they provide free 
fatty acids for energy or storage. Upon lipolysis, chylomicrons 
and VLDL are depleted of TG and enriched in cholesterol, resulting 
in the formation of chylomicron remnants and VLDL remnants. 
In addition, their cholesterol content is further enhanced by the 
action of cholesterol ester transfer protein (CETP). Since most 
cells can degrade TG, and there are not any cells that can degrade 
cholesterol, the cholesterol content of TRLs is more likely to be the 
cause of atherosclerosis and cardiovascular disease rather than 
raised TG per se. Indeed, cholesterol, rather than TG accumulates 
in intimal foam cells and in atherosclerotic plaques, and remnant 
lipoproteins, much like LDL can enter the arterial intima. In contrast, 
chylomicrons are too large to enter. Lipoprotein lipase activity at 
the surface of remnant particles, either at the surface of vascular 
endothelium or within the intima, leads to liberation of free fatty 
acids, monoacylglycerols, and other molecules, each of which 
could cause local injury and inflammation. Although other possible 
mechanisms have been suggested, perhaps the simplest chain of 
events is that high triglyceride concentrations are a marker for 
raised remnants rich in cholesterol, which, upon entrance into 
the intima, leads to low-grade inflammation, foam cell formation, 
atherosclerotic plaques, and ultimately cardiovascular disease and 
increased mortality. (Fig.).11-15)
Remnant cholesterol is the cholesterol content of TRLs 
(chylomicron remnants, VLDL, and IDL) in the fasting or non-fasting 
states. Because a direct assay that measures all remnants at the 
same time has not yet been developed, remnant cholesterol can be 
calculated as non-fasting total cholesterol minus HDL cholesterol 
minus LDL cholesterol.11) A recent study has shown that remnant 
cholesterol levels in TRLs are causal in ischemic heart disease 
independent of reduced HDL cholesterol.16) Because the level of TG 
is significantly correlated with the amount of remnant cholesterol 
in TRLs (r=0.96), the amount of TG may represent the level of 
remnant cholesterol.16) Therefore, the level of TG is a biomarker for 
circulating TRLs and their metabolic remnants.17)
TRLs drive atherothrombosis via a number of mechanisms. 
Particle size is a key limiting factor influencing the retention 
of apolipoprotein B containing lipoproteins. Although large 
chylomicrons (70 nm diameter) do not penetrate the arterial wall, 
Table 1. Causal and observational risk estimates for ischemic heart disease16)
Hazard/odds ratio p p for comparison
Remnant cholesterol Observational: elevated plasma levels 1.37 (1.27-1.47) 5x10-17 3x10-4
Causal: genetically elevated levels 2.82 (1.92-4.15) 1x10-7
Remnant cholesterol to HDL cholesterol ratio Observation: elevated plasma levels 1.23 (1.19-1.27) 9x10-33 1x10-4
Causal: genetically elevated levels 2.94 (1.90-4.55) 1x10-6
HDL cholesterol Observational: reduced plasma levels 1.55 (1.43-1.68) 9x10-27 0.02
Causal: genetically reduced levels 0.74 (0.40-1.37) 0.3
LDL cholesterol Observational: elevated plasma levels 1.14 (1.10-1.18) 2x10-14 7x10-6
Causal: genetically elevated levels 1.47 (1.32-1.63) 4x10-13
HDL: high-density lipoprotein, LDL: low-density lipoprotein
Table 2. Studies for the use of non-fasting TG and remnant cholesterol levels as predictors of CVD events
Primary endpoint Sample size Primary endpoint Hazard ratio (95% CI)
Varbo et al.16)
Incidence of CVD with 88.41 mg/dL increase in
 non-fasting remnant cholesterol 
73513 1.4 (1.3-1.5)
Nordestgaard et al.27)





The Women’s Health Study28)
Incident CVD, non-fatal MI, non-fatal stroke, 
coronary revascularization or cardiovascular death
26509 2.53 (1.69-3.79)
Jørgensen et al.30)
Incidence of MI with genetically elevated doubling of 
non-fasting TG and remnant cholesterol 
10391 1.87 (1.25-2.81)
TG: triglyceride, CVD: cardiovascular disease, CI: confidence interval, MI: myocardial infarction
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smaller remnants of chylomicrons and large VLDL, as well as LDL 
and lipoprotein (a) enter the arterial wall and therefore enhance 
cholesterol accumulation directly.18) These TRL remnant particles 
contribute directly to plaque formation and progression.19) In 
addition, TRLs promote endothelial dysfunction by increasing 
immune inflammatory responses and destabilize plaque, enhance 
thrombus formation, promote secretion of tissue factor, fibrinogen, 
coagulation factors VII, XII, impair fibrinolysis, and increase 
plasminogen activator inhibitor-1 secretion.19-24)
Epidemiologic evidence
Previous studies have shown that elevated fasting and non-fasting 
hypertriglyceridemia or very low-density lipoprotein cholesterol were 
associated with increased risk of coronary heart disease, even after 
adjustment for HDL cholesterol concentrations.9)25)26) Recent studies 
demonstrated that raised TG was strongly associated with increasing 
risks of cardiovascular disease. Raised non-fasting TG was strongly 
associated with increasing risks of myocardial infarction, ischemic 
heart disease, ischemic stroke, and all-cause mortality.27-30) Raised 
fasting and non-fasting TG were associated with an increased risk 
of coronary heart disease in an Emerging Risk Factors Collaboration 
study.31) This association was attenuated after adjustment for HDL 
cholesterol and non-HDL cholesterol. In multivariate analyses, the 
relationship between TG and cardiovascular diseases (CVD) is either 
attenuated or lost, thereby suggesting that the cholesterol content 
of TRLs or remnant cholesterol is causative for CVD rather than 
raised TG itself. In addition, data from three major Danish studies 
provides support for remnant cholesterol in TLRs as a causal factor for 
CVD by Mendelian randomization study.9)16)30) In these studies, a 39 
mg/dL increase in non-fasting remnant cholesterol was associated 
with a 2.8 fold causal risk for ischemic heart disease which was 
higher than for observational data alone (hazard ratio 1.4, 95% 
confidence interval 1.3 to 1.5) and independent of HDL cholesterol 
concentration.16) These genetic studies reinforce the role of remnant 
cholesterol in TRLs rather than TG as a cardiovascular risk factor 
(Table 1). For non-fasting remnant cholesterol alone, for the ratio 
of non-fasting remnant cholesterol to HDL cholesterol, and for LDL 
cholesterol alone, causal risk estimates for genetically elevated 
levels were in the same direction and higher than corresponding 
risk estimates for corresponding increases in conventional plasma 
levels of the same lipoproteins; however, this was not the case for 
HDL cholesterol alone.16) These results demonstrated the important 
role of non-fasting remnant cholesterol, the ratio of non-fasting 
remnant cholesterol to HDL cholesterol, LDL cholesterol on the 
risk of ischemic heart disease than HDL cholesterol in general 
population. 
Remnant cholesterol was causative for ischemic heart disease 
independent of HDL cholesterol levels (Table 2).32) In these studies, 
remnant cholesterol was estimated indirectly as total cholesterol minus 
the cholesterol contents of LDL and HDL. These population based studies 
clearly demonstrated a role of non-fasting TG and remnant cholesterol 
levels on the predictions of CVD events in general population. In the 
statin era, among patients receiving statin therapy after acute coronary 
syndrome, on-treatment TG≤150 mg/dL was associated with a lower 
risk of recurrent coronary heart disease events independently of 
the level of LDL cholesterol.33) Among patients with acute coronary 
syndrome treated effectively with statins, fasting TG predicts long-term 
and short-term cardiovascular risk.33) These data support the concept 
that achieving both low LDL cholesterol and low TRLs may be important 
therapeutic goals in patients following acute coronary syndrome.
Table 3. Observational and causal (by use of genetics) associations of raised remnant cholesterol and TG with risk of ischemic heart disease, myocardial 
infarction and all cause mortality11)
N total N events Odds ratio (95% CI)
Ischemic heart disease
Remnant cholesterol increase of 39 mg/dL
Observational 56667 2874 1.4 (1.3-1.5)
Causal using genetics 73513 11984 2.8 (1.9-4.2)
Myocardial infarction
Remnant cholesterol doubling in concentration Observational 10394 1098 1.7 (1.4-2.0)
Causal using genetics 60113 5705 2.2 (1.5-3.4)
Triglyceride doubling in concentration Observational 10391 1098 1.6 (1.3-1.9)
Causal using genetics 60113 5705 1.9 (1.4-2.7)
All cause mortality
Triglyceride increase of 88.41 mg/dL
Observational 13957 9991 1.2 (1.1-1.2)
Causal using genetics 10208 4005 2.0 (1.2-3.3)
TG: triglyceride, CI: confidence interval 
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Genetic evidence
The genetic basis of mild to moderate hypertriglyceridemia with 
or without elevated LDL cholesterol in most individuals is polygenic. 
Postprandial TG metabolism abnormalities are strongly associated 
with single nucleotide polymorphisms at common genetic loci. 
Candidate genes associated with postprandial lipemia include 
apolipoprotein A1, A4, A5, C3, E, lipoprotein lipase, fatty acid 
binding protein 2, microsomal transfer protein (MTP), scavenger 
receptor B1, Angiopoietin-like proteins (ANGPTL)4 and peroxisome 
proliferator-activated receptor (PPAR) α.32)34)
Recent Mendelian randomization studies with genetic variants 
reported several candidate genes that affect the concentrations of 
remnant cholesterol. The relative risks of remnant cholesterol on 
ischemic heart disease and all-cause mortality according to causal 
genetic variants compare with corresponding observational results 
are shown in Table 3. 
Lipoprotein lipase (LPL) is the key TG regulating enzyme, which 
hydrolyzes TG in the circulation and promotes the hepatic uptake 
of TRLs. A common gain of function LPL variant, S447X, confers an 
anti-atherogenic lipid profile characterized by low levels of TG and 
lower incidence of vascular disease or myocardial infarction.35)36) 
In contrast, several loss of function LPL variants associated with 
elevated TG levels which have been associated with increased 
coronary artery disease (CAD) risk.37)38) It was identified as common 
non-coding variants at the LPL gene locus associated with both TG 
and CAD risk in the same direction by genome wide association 
studies.39-41) Beyond LPL itself, common variants that influence TG 
levels are significantly associated with CAD risk even after adjusting 
for their effects on other lipid traits.42) Among the common variants 
with strong associations with both TG and CAD were those at a 
gene locus containing the genes apolipoprotein C3 (APOC3) and 
apolipoprotein A5 (APOA5) which encode apoC-III and apoA-V, 
respectively, and are found on TRLs and known to be the regulators 
of LPL activity and TG levels.43)
ApoC-III is a key regulator of fasting and postprandial plasma 
TG levels and TG homeostasis. It is synthesized principally in 
the liver and expressed in the liver and intestine and circulates 
on and exchanges between TRLs and HDL.44)45) ApoC-III inhibits 
LPL-mediated hydrolysis of TRLs and adversely affects receptor-
mediated hepatic uptake of remnants of TRLs.45) At higher 
concentrations, ApoC-III also inhibits the activity of hepatic 
lipase, an enzyme that plays an important role in the conversion 
of VLDL to IDL and LDL, as well as in the remodeling of HDL. Thus, 
elevated levels of ApoC-III in plasma have been associated with 
both impaired lipolysis and impaired clearance of TRLs from the 
circulation, which results in the accumulation of atherogenic 
VLDL and chylomicron remnants.45) Furthermore, some study 
suggested that ApoC-III has direct proinflammatory effects at 
the level of the vessel wall.46)47) Elevated ApoC-III levels are an 
independent risk factor for cardiovascular disease and genetic 
variants that result in a loss of function and attenuated levels of 
ApoC-III in plasma are associated with a reduced risk of coronary 
heart disease.45)48)
APOA5 is thought to play a crucial role in TG metabolism. APOA5 
knockout mice demonstrate profound TG, whereas human APOA5 
transgenic mice have significantly lower plasma TG than controls.51) 
Studies of APOA5 have revealed several coding variants have been 
implicated in severe hypertriglyceridemia or hyperchylomicronemia 
and some common coding variants have also been attributed 
to increased CAD risk.52-54) In addition, carriers of rare non-
synonymous mutations at APOA5 were at a 2.2 fold increased 
risk for myocardial infarct when compared with non-carriers.55) 
Analysis of a specific APOA5 variant (1131T>C) that regulates 
pathways of TG metabolism showed an association with coronary 
risk. The increase in risk per allele was also concordant with data 
from observational studies.56) Taken together, these recent studies 
have provided powerful evidence that plasma levels of TRLs are 
causally related to the development of CAD and specifically that 
apoC-III promotes and APOA5 protects against CAD.43) In addition, 
these offer strong support to the hypothesis that intervention to 
lower TRL levels may decrease the risk of CAD. 
Taken together, genetic studies strongly support the theory that 
high concentrations of TRLs or remnant cholesterol are causal risk 
factors for cardiovascular disease and all-cause mortality, and that 
low HDL cholesterol might merely be a long-term marker of raised 
TG and remnant cholesterol.11)
Recent Evidence on Hypertriglyceridemia and  
Remnant Cholesterol as a Therapeutic Target for 
Reduction of Residual Cardiovascular Risk
General measure and lifestyle interventions
First, secondary causes of hypertriglyceridemiasuch as nephrotic 
syndrome, alcohol, or obesity should be ruled out and treated. In 
addition, intensive lifestyle intervention is the fundamental first 
step in the management of patients with hypertriglyceridemia 
or cardiometabolic disease. This includes to smoking cessation, 
increased physical activity, adoption of a Mediterranean style 
diet, replacing saturated fats with unsaturated ones, reduction of 
carbohydrate content in the diet, avoidance of refined sugar and 
fructose, increased intake of complex carbohydrates with high 
soluble fiber, weight loss and limited alcohol intake. If TG levels 
remain elevated, pharmacological approaches including fibrates 
and omega-3 fatty acids are considered.
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Treatment options for hypertriglyceridemia and remnant 
cholesterol
Fibrates and omega-3 fatty acids 
Fibric acid is a synthetic ligand of the nuclear receptor PPAR α that 
is highly expressed in skeletal muscle and the heart where it promotes 
ß-oxidation of fatty acids to mediate hypolipidemic actions. PPAR 
α regulates expressions of key proteins involved in atherogenesis, 
vascular inflammation, plaque stability, and thrombosis.57)58) Thus, 
PPAR α may exert direct anti-atherogenic actions in the vascular 
wall. Fibrate, PPAR α agonist, therapy significantly improves the 
lipoprotein profile and the flow-mediated dilator response to 
hyperemia, reduces levels of inflammatory markers, increases 
adiponectin levels, and improves insulin sensitivity..57-60) The 
beneficial effects of fibrate on endothelial function, inflammation, 
and insulin sensitivity are highly relevant to CVD and are likely to 
simultaneously improve both cardiovascular and metabolic health in 
patients with hypertriglyceridemia. Fibrate therapy improved clinical 
outcomes in primary and secondary prevention trials especially in 
patients with low HDL cholesterol and high triglycerides, despite the 
use of established therapy.61)62)Although the combination of statins 
and gemfibrozil is more likely to be accompanied by myopathy due to 
significant pharmacokinetic interactions with statins,63) fenofibrate 
showed no significant side effects with combination treatment with 
statins.64)65) Fenofibrate did not reduce events overall in the trials, 
except in patients with high triglycerides and low HDL cholesterol 
subgroups. However, the failure of fenofibrate in other patients has 
been blamed due to several issues such as pretty low triglycerides 
levels.11) On the other hand, we discussed off-target effects of 
fibrates such as anti-inflammatory effect.57-60) Indeed, while fibrates 
appear to work, their benefit does not associate with TG lowering. In 
other words, a high TG patient may be more likely to benefit, but not 
necessarily due to TG lowering itself.
Omega-3 fatty acids consumption also improves triglycerides 
level and endothelial function, however, demonstrates inconsistent 
effects on inflammation, insulin resistance, and hemostasis.58)66) 
Although omega-3 fatty acids are bioactive compounds that 
play a significant role in cardiovascular and metabolic health and 
produce modest reductions in the rates of cardiovascular death 
in earlier randomized clinical trials, however, recent double-blind, 
randomized, clinical trials failed to show beneficial effects on 
cardiovascular events under modern guideline therapy.67)68) Further, 
omega-3 fatty acid or fish consumption was associated with 
a modestly higher incidence of type 2 diabetes in observational 
studies.69)70) However, this untoward effect seems to be neutral.
Taken together, fibrates might play an important role in the 
reduction of residual cardiovascular risk by favorable lipid profiles, 
endothelial function, inflammation and metabolic effects in 
patients with cardiovascular risks especially low HDL cholesterol 
and high triglycerides.3)11)58)62) However, a large-scaled clinical trial 
to investigate the effects of fibrate based on statin in patients 
with low HDL cholesterol and high TG level on the cardiovascular 
outcomes will be needed in the future. Though some studies 
reported no different effects of high dose omega-3 fatty acids 
except the reduction of triglycerides level,71) the role of omega-3 
fatty acids, particularly a high dose, will be further elucidated with 
regard to the reduction of residual cardiovascular risk in the future. 
Three ongoing randomized controlled clinical trials (the Rischio and 
Prevenzione study),72) a Study of Cardiovascular Events in Diabetes 
(ASCEND, NCT00135226), the Vitamin D and Omega-3 Trial (VITAL, 
NCT01169259)73) in patients with low cardiovascular risk will 
further answer this question. In patients with high cardiovascular 
risk, reduction of cardiovascular events with EPA-intervention trial 
(REDUCE-IT, NCT 01492361) and outcomes study to assess residual 
risk reduction with epanova (STRENGTH, NCT02104817) are ongoing 
and will answer the effectiveness of high dose omega-3 fatty acids 
added on statin treatment for the cardiovascular outcomes.11)
Niacin, Bile acid binding resin and cholesteryl ester transfer protein 
Niacin has a broad spectrum of lipid modifying activity which 
include HDL cholesterol raising and TG lowering effects.74) Although 
previous studies reported niacin had shown attenuation of 
atherosclerosis progression and reduction of non-fatal myocardial 
infarction and all-cause mortality,75)76) niacin has now been 
withdrawn following reports of safety issues in the HPS2-THRIVE 
trial.77) Bile acid binding resins are indicated for treatment of elevated 
plasma LDL cholesterol levels. Although hypertriglyceridemic 
patients with elevated LDL cholesterol levels are indicated the 
use of bile acid binding resins, most hypertriglyceridemia patients 
without elevated LDL cholesterol levels are contraindicated 
due to no effect or mild elevation of TG or an adverse effect on 
plasma TG concentration.78) Because CETP promotes exchange of 
cholesterol and TG between HDL and TRL, LDL and CETP inhibitors 
are expected to have anti-atherogenic effects by increasing the 
concentration of cholesterol in the protective HDL fraction, and 
decreasing proatherogenic LDLs or the cholesterol content of 
TRLs.79) However, recent large scaled randomized clinical trials 
such as ILLUMINATE and dal-OUTCOMES failed due to safety 
concerns or futility in major outcomes.80)81) It was explained that 
it was mainly due to adverse off-target effects or dysfunctional 
HDL. Therefore, currently CETP inhibitors are not recommended to 
management of hypertriglyceridemia. In addition, we need to wait 
the results of on-going clinical trials of CETP inhibitors including 
Randomized Evaluation of the Effects of Anacetrapib Through 
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Lipid-modification (NCT01252953) and A Study of Evacetrapib in 
High-Risk Vascular Disease (ACCELERATE, NCT01687998).82) 
Antisense inhibition of apolipoprotein C-III 
ISIS 304801 is a second generation antisense inhibitor of 
APOC3 synthesis. This small chemically-modified oligonucleotide 
is delivered subcutaneously and is internalized in the liver where 
it inhibits the translation of APOC3 mRNA and promotes mRNA 
degradation through activation of RNase H.43) A randomized, 
double-blind, placebo controlled, dose ranging, phase 2 study 
revealed that treatment with ISIS 304801, at doses ranging 
from 100 to 300 mg, once weekly for 13 week, resulted in dose-
dependent and prolonged decreases in plasma APOC3 levels when 
the drug was administered as a single agent.45) In addition, when it 
was administered as in combination with fibrates, treatment with 
ISIS 304801 resulted in reduction of APOC3 levels. Concordant 
reductions of 31.3 to 70.9% were observed in TG levels without 
any safety concerns. This study provides evidence for a causal 
relationship between APOC3 and TG metabolism. In addition, 
it supports the continued development of ISIS304801 for the 
treatment of patients who remain at risk for cardiovascular events 
and pancreatitis because of very high TG levels. 
Angiopoietin-like proteins, Angiopoietin-like proteins 3 and 
Angiopoietin-like proteins 4 
Like apoC-III, ANGPTL3 and ANGPTL4 are thought to inhibit 
LPL activity, leading to elevate plasma TG levels. Pharmacological 
inhibition of these ANGPTLs could reduce plasma TG by a 
mechanism similar to that of anti-APOC3-focused therapies and 
result in reduced CAD risk.43) However, recent evidence linking 
ANGPTL3 and ANGPTLs loss of function to CAD risk has been 
smaller or inconsistent.83-85)
Microsomal triglyceride protein  inhibitor (lomitapide), diacylglycerol O 
acyltransferase 1 inhibitor, lipoprotein lipase gene replacement treatment
Lomitapide, an MTP inhibitor that interferes with apoB containing 
lipoprotein assembly in the apoB100 and apoB48 pathway, reduces 
both chylomicron and VLDL secretion.32) It is currently available for 
the management of homozygous familial hypercholesterolemia 
to treat a patient with extremely severe hypertriglyceridemia due 
to LPL deficiency.86) The limitation of lomitapide treatment is the 
possibility of developing steatohepatitis and fibrosis. The research 
for DGAT1 and LPL gene replacement treatment is still being tested. 
Summary and Future Perspectives
Residual cardiovascular risk still exists even after optimal 
medical treatment including high dose statin treatment. After 
failure of HDL cholesterol raising treatment and genetic studies 
on HDL cholesterol, concern of the role of TRLs and remnant 
cholesterol regarding cardiovascular risk are increasing. 
Experimental, epidemiological and genetic evidence support the 
harmful effects of TRLs and remnant cholesterol. To reduce risk 
by hypertriglyceridemia, lifestyle intervention plays a key role. 
However, when hypertriglyceridemia or high levels of TRLs or 
non-HDL cholesterol are not corrected after lifestyle intervention 
with statin treatment, current available drugs such as fibrates are 
options for management of hypertriglyceridemia. Omega-3 fatty 
acids should be held until ongoing clinical trials are reported. In 
addition, new treatment options such as antisense inhibition of 
apolipoprotein C-III, ANGPTLs are being tested. The effectiveness 
of treatment of hypertriglyceridemia on cardiovascular outcomes 
will be answered in the future. 
Conclusions
There is increasing evidence of the role of hypertriglyceridemia, 
TRLs and remnant cholesterol on cardiovascular outcomes. Effort 
for reducing levels of TG and TRLs including correction of secondary 
cause of hypertriglyceridemia and lifestyle intervention, fibrates, 
omega-3 fatty acids and new treatment options are encouraging. 
Randomized clinical trials of these treatments on beneficial 
cardiovascular outcomes are ongoing and will answer the exact 
role of treatment of TG and TRLs in the future. 
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